Eleventh Circuit Revives False Claims Act Whistleblower Suits, Reversing a Tampa Ruling That Struck Them Down

A unanimous three-judge panel of the U.S. Court of Appeals for the Eleventh Circuit has reversed a Tampa federal judge's ruling that the whistleblower provisions of the False Claims Act violate the Constitution, restoring the ability of private citizens to bring fraud suits on behalf of the federal government throughout Florida, Georgia and Alabama.

The September 1 opinion, written by Judge Elizabeth Branch, held that a False Claims Act relator is not an Officer of the United States because the relator does not occupy a continuing position established by law. That conclusion defeats the Appointments Clause challenge that had persuaded the district court.

The underlying case was brought by Clarissa Zafirov, a board-certified family care physician who alleged that her former employer systematically submitted false Medicare Advantage diagnosis codes to inflate monthly risk-adjustment payments. U.S. District Judge Kathryn Kimball Mizelle had dismissed the case with prejudice in 2024 after concluding that Zafirov lacked constitutional authority to prosecute it.

What the appeals court held

The Appointments Clause requires that officers of the United States be appointed by the president, by courts of law or by heads of departments. Judge Mizelle had reasoned that a False Claims Act relator exercises significant executive authority by litigating on behalf of the United States, that neither the executive branch nor a court appoints relators, and that the provisions are therefore unconstitutional.

The Eleventh Circuit accepted the premise that the Appointments Clause governs officers but rejected the conclusion that a relator is one. The panel's reasoning turned on the requirement that an officer occupy a continuing position established by law. A relator files one case, litigates that case and has no ongoing role, which the court found falls outside the definition.

The distinction is narrower than it may appear, and the panel did not resolve the broader constitutional question. The court left other challenges unanswered, including arguments grounded in Article II and the president's authority to control executive power, and remanded the case to the district court for further proceedings.

That means the qui tam provisions survive this particular challenge without being definitively vindicated. Legal commentators have described the ruling as allowing qui tam to fight another day rather than as settling the question, and several have noted that the Supreme Court is a plausible next stop.

How the False Claims Act works

The False Claims Act dates to 1863, when Congress enacted it in response to contractors defrauding the Union Army during the Civil War. Its central innovation was the qui tam provision, which allows a private person with knowledge of fraud against the government to file suit in the government's name and to receive a share of any recovery.

The mechanics are specific. A relator files the complaint under seal, and the Justice Department investigates while the case remains sealed and not served on the defendant. The government may intervene and take over the litigation, or it may decline and allow the relator to proceed alone. Recoveries are shared, with the relator's portion generally ranging from 15 to 30 percent depending on whether the government intervened.

The statute has become the federal government's primary tool against fraud on public programs. Recoveries have totaled tens of billions of dollars over the past several decades, with health care fraud accounting for the largest share, followed by defense contracting and other procurement.

The economic logic is that fraud is detected by people inside organizations rather than by auditors outside them. An employee who sees improper billing has information no government investigator can obtain, and the financial award plus anti-retaliation protections are the incentive that overcomes the substantial personal cost of reporting.

What the case was about

Zafirov's allegations concern Medicare Advantage risk adjustment, a payment mechanism that is technical but consequential. Under Medicare Advantage, the federal government pays private insurers a fixed monthly amount per enrollee, adjusted upward for enrollees with documented health conditions expected to require more care.

That structure creates a financial incentive to document diagnoses. An enrollee coded with additional qualifying conditions generates a higher monthly payment regardless of whether additional care is actually provided, which is why risk-adjustment accuracy has become one of the most heavily litigated areas in health care fraud enforcement.

Zafirov alleged that her former employer, a primary care organization, submitted diagnosis codes that were not supported by the patients' actual conditions, inflating the risk scores and the resulting payments. Those allegations remain allegations; the case was dismissed on constitutional grounds before any determination on the merits, and the remand returns it to the district court.

The case is one of many nationally targeting Medicare Advantage risk adjustment. Federal enforcement in this area has grown as Medicare Advantage enrollment has expanded to cover more than half of all Medicare beneficiaries.

Why Florida has an outsized stake

Florida has more Medicare beneficiaries than almost any state and one of the highest Medicare Advantage penetration rates in the country. The state's population skews older, and its managed care market is among the most developed, which together make Florida the center of gravity for Medicare Advantage litigation.

The state is also a longstanding focal point for health care fraud enforcement generally. The Justice Department has operated health care fraud strike forces in Miami and Tampa for years, and South Florida in particular has produced a disproportionate share of federal prosecutions involving durable medical equipment, home health, pharmacy and infusion billing.

Had Judge Mizelle's ruling stood, the practical effect within the Eleventh Circuit would have been the elimination of private whistleblower suits across Florida, Georgia and Alabama. Because Florida generates so much qui tam activity, that would have removed a significant portion of the national enforcement apparatus.

It would also have created a circuit split, with qui tam available in most of the country but unavailable in the Southeast. That kind of geographic inconsistency in federal law is among the strongest indicators that the Supreme Court will eventually take a case.

What it means for Floridians

For Florida patients and taxpayers, the direct interest is program integrity. Medicare and Medicaid fraud drains funds from programs Florida residents depend on, and the qui tam mechanism recovers money that would otherwise be lost. Recoveries return to the Treasury and to state Medicaid programs.

For Florida health care workers, the ruling preserves a specific legal option. A nurse, physician, billing specialist or administrator who observes improper billing retains the ability to bring a case and to receive a share of any recovery, along with the statute's protections against retaliation.

For Florida health care employers, the compliance obligation is unchanged from what it was before the district court ruling. Organizations that had begun treating the Mizelle decision as reducing their exposure within the Eleventh Circuit should understand that the exposure has been restored.

For Florida businesses generally, the reach extends well beyond health care. The False Claims Act applies to any claim submitted to the federal government, which in Florida includes defense contracting around the state's military installations, disaster recovery and FEMA-funded work, federal grants to universities, and transportation projects using federal funds.

The litigation ahead

The case returns to the district court on remand, where the unresolved constitutional arguments and, potentially, the merits of Zafirov's allegations remain to be addressed. Judge Mizelle's original ruling did not reach the substance of the fraud claims.

The Article II arguments the Eleventh Circuit left open are the ones defense counsel are most likely to press next. Those contend that even if a relator is not an officer, the qui tam structure improperly limits the president's control over executive enforcement decisions, a theory that has gained traction in recent separation-of-powers litigation.

Petition for Supreme Court review is a realistic possibility from either direction as the case develops. Several Justices have expressed interest in revisiting qui tam's constitutionality, and the Court has taken cases in this area before.

Congress could also act. The qui tam provisions are statutory, and legislation could restructure them to address constitutional objections while preserving the whistleblower incentive. No such proposal is currently moving.

The seal period is one feature of the statute worth understanding, because it explains why the public rarely learns about these cases until years after filing. A complaint can remain under seal for extended periods while the government investigates, and defendants sometimes do not know a case exists until the government makes an intervention decision.

Anti-retaliation protection is the other feature that matters practically. The statute provides a cause of action for an employee who is fired, demoted or otherwise penalized for reporting, and that protection applies whether or not the underlying fraud case ultimately succeeds.

What is next

The immediate practical effect is that qui tam cases proceed normally in Florida, Georgia and Alabama, including cases that had been stayed or dismissed in reliance on the district court ruling. Relators whose cases were affected will be seeking to revive them.

Enforcement volume should return to its prior pattern. The Justice Department's health care fraud units in Miami and Tampa depend substantially on relator-initiated cases, and the uncertainty of the past two years had a chilling effect on filings within the circuit.

The broader constitutional question remains genuinely open. Both the remand proceedings and parallel litigation in other circuits will shape how the Article II theory develops, and the eventual resolution will determine whether a 163-year-old enforcement mechanism survives in its current form.

For now, the law within the Eleventh Circuit is what it was before 2024. A Florida employee who discovers fraud against a federal program can bring a case, and the statute that has recovered tens of billions of dollars for the Treasury remains operative in the state that generates more of those cases than almost any other.